Form 8-K - Current report:
SEC Accession No. 0001628280-18-012707
Filing Date
2018-10-19
Accepted
2018-10-19 17:16:58
Documents
2
Period of Report
2018-10-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K REVOLVER EXPANSION revolverexpansion.htm 8-K 28768
2 EXHIBIT 10.1 revolveragreementexpansion.htm EX-10.1 17290
  Complete submission text file 0001628280-18-012707.txt   47278
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 181131036
SIC: 2834 Pharmaceutical Preparations